Utah-based AI biotechnology company Recursion Pharmaceuticals has secured USD 50 million as private investment in public equity (PIPE) from NVIDIA to accelerate the development of AI models for drug discovery. In relation to this, Recursion will also partner with NVIDIA to leverage the latter's cloud services.
The funding and partnership will facilitate the training of AI foundation models for drug discovery by leveraging Recursion’s proprietary biological and chemical dataset—with over 23 petabytes and three trillion searchable gene and compound relationships—and NVIDIA’s DGX cloud. NVIDIA will also offer its AI stack and full-stack computing expertise to Recursion.
NVIDIA is expecting to commercially license or release the AI models on its cloud service for generative AI in drug discovery BioNeMo, while Recursion plans to leverage the cloud service to advance its internal therapeutic pipeline and of its partners.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.